Minimal residual disease (MRD) testing, like OncoDxRx's OncoMRD, appears to be a valuable tool for predicting outcomes and potential relapse in patients with cancer.
OncoDxRx’s PGA test provides access – the ability to find a way around. The one-of-a-kind technology can “re-measure the geometry of the tumor with regard to access to more therapeutic options”.
A new "build-for-purpose” test was unveiled by OncoDxRx. The proprietary technology aims at broadening the coverage of tailored personalized diagnostics and therapeutics to those cancer patients currently excluded from precision medicine.